Vaccine for Prevention of Rabies Infections in Humans

Tech ID
EH01001
Background

Researchers at Wistar have developed a new rabies vaccine that has the potential to produce the long-lasting immunity to rabies that is required for an effective prophylactic vaccine. This vaccine is derived from recombinant chimpanzee adenovirus (rAdC68) that contains the DNA sequence of the rabies glycoprotein.

In non-human primates, this adenovirus-based vaccine produces long-lasting immunity after just one intramuscular injection, even in the presence of pre-existing immunity to human adenovirus. In ongoing studies, primates immunized with one does of the rAdC68 rabies vaccine showed no decline in serum antibody levels after six months. Wistar is seeking a partner to develop this vaccine for prevention of human rabies infection, either as a single vaccine or in combination with the current human diploid cell rabies vaccine. The adenovirus-based vaccine is less expensive to produce, maintain, and distribute than the current human rabies vaccines. This new immunization approach may make it feasible and cost-effective to administer prophylactic rabies vaccines to children in areas where rabies still commonly infects dogs and other companion animals.

Key Words
adenovirus vector, rabies, rabies vaccine, Vaccine
Applications and Advantages

The recombinant chimp adenovirus-based rabies vaccine can induce long-lasting immunity to rabies after a single immunization. Such a vaccine has the potential to be less expensive to produce and administer than the current PEP treatment regimen, which requires multiple immunizations in combination with immune globulin.

Intellectual Property Status

Wistar will provide prospective partners with the appropriate materials (rAdC68 expressing rabies glycoprotein) to develop vaccines for use in Asia and Africa. Non-exclusive or exclusive licenses will be considered.